Yesterday I shared a video from a 34-year-old doctor who personally takes low-dose (1.25mg) Tirzepatide every week.
He made another video.
This one is about Retatrutide, the new triple agonist that’s been generating a lot of buzz lately.
Before getting into the numbers, here’s what “triple agonist” actually means.
Tirzepatide targets two receptors:
- GLP-1: Suppresses appetite, slows digestion, reduces food noise
- GIP: Works alongside GLP-1 to amplify the appetite-suppressing and fat-loss effects
Retatrutide keeps both and adds a third:
- Glucagon: Increases the metabolism to some extent
On paper, that sounds like an upgrade (3 compounds vs 2).
In practice, it’s where things get complicated.
The Headline Number Is Misleading
The study everyone is citing shows 28.7% weight loss over 68 weeks [1]. That sounds incredible until you look at how it was calculated. That figure comes from what’s called an efficacy estimate, meaning it only counts people who followed the protocol perfectly.
But that’s not the standard way these trials are usually reported. The standard metric is called the treatment regimen estimate, which includes everyone who started the drug, including people who dropped out.
The more honest number, the one that accounts for everyone who actually started the treatment, comes in at 23.7%.
Tirzepatide’s equivalent figure? 20.9% [2].
So the real-world gap between these two drugs is about 3%.
That’s the actual story behind the headline.
The Side Effect Profile Is a Problem
The doctor points out that phase 2 data flagged elevated resting heart rate and heart rhythm problems [3] tied to the glucagon component.
The same mechanism that ramps up metabolic rate also puts more demand on your cardiovascular system.
His bigger concern is that we don’t have a long-term cardiovascular outcomes trial for Retatrutide yet. That data simply doesn’t exist.
There’s also dysesthesia to consider. A condition where touching your skin causes pain, itching, or tingling.
With Tirzepatide, roughly 0.4% of participants reported it, with Retatrutide at the highest dose, that jumped to 21%.
There’s also a lean-muscle trade-off when you take Retatrutide…
The phase 2 trial showed a 37% loss of lean body mass vs 25% with tirzepatide.
*Note: Losing a bit of muscle is an unavoidable part of weight loss, but Retatrutide seems to burn a higher percentage of muscle for every pound lost (about 50% more than tirzepatide).
In my opinion, you don’t need that third compound (Glucagon).
Tirzepatide works incredibly well, as is, with GLP-1 and GIP.
*I am now getting DMs daily like this about Kino Clinic Tirzepatide.
His Conclusion
The doctor’s take is clear.
If someone isn’t hitting their goals on Tirzepatide, Retatrutide might be an option down the road. But with the current safety picture, he wouldn’t reach for it as a first-line choice over Tirzepatide.
I fully agree with this take.
With my system + Tirzepatide, you should be able to get as lean as you desire anyway.
With Tirzepatide, I’m to the point where I even have to purposely go out of my way to eat more food, so I don’t get too lean.
Retatrutide is helpful for someone who genuinely struggles with creating a deficit.
But a massive deficit isn’t the goal.
The goal is to strip off pure fat and hold muscle. Chasing faster weight loss usually just comes at the expense of muscle.
So for most people, tirzepatide is the Goldilocks option
And reta often can backfire.
Tirzepatide remains the smarter option, which is why we offer it at Kino Clinic.
Physician-prescribed compounded Tirzepatide at $179 per month.
Fill out a quick online form, a licensed physician reviews it, and if approved, your medication arrives within 3-5 business days. The whole process is online.
No phone calls, no video appointments.
Talk soon,
Greg O’Gallagher
Kino Clinic works exclusively with licensed 503A compounding pharmacies to provide physician-prescribed, pharmacy-grade compounded Tirzepatide. All medications are prescribed by licensed physicians for individually identified patients based on documented clinical need. Compounded medications are not FDA-approved finished drug products and are not intended as substitutes for FDA-approved medications such as Mounjaro® or Zepbound®. Individual results vary. This is not medical advice. Use only under the supervision of a licensed healthcare provider.
© 2026 Kino Clinic. All rights reserved.